Antagonists of activin signaling: mechanisms and potential biological applications

被引：179
作者：
Harrison, CA
Gray, PC
Vale, WW
Robertson, DM
机构：
[1] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia
[2] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2005年 / 16卷 / 02期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1016/j.tem.2005.01.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Activins are members of the transforming growth factor-beta (TGF-beta) superfamily that control many physiological processes such as cell proliferation and differentiation, immune responses, wound repair and various endocrine activities. Activins elicit these diverse biological responses by signaling via type I and type II receptor serine kinases. Recent studies have revealed details of the roles of inhibin, betaglycan, follistatin and its related protein follistatin-related gene (FLRG), Cripto and BAMBI in antagonizing activin action, and exogenous antagonists against the activin type I (SB-431542 and SB-505124) and type II (activin-M108A) receptors have been developed. Understanding how activin signaling is controlled extracellularly is the first step in providing treatment for wound healing and for disorders such as cachexia and cancer, which result from a deregulated activin pathway.
引用
收藏
页码：73 / 78
页数：6
相关论文
共 61 条
[1]   Cripto: A tumor growth factor and more [J].
Adamson, ED ;
Minchiotti, G ;
Salomon, DS .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 190 (03) :267-278
[2]   Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo [J].
Adkins, HB ;
Bianco, C ;
Schiffer, SG ;
Rayhorn, P ;
Zafari, M ;
Cheung, AE ;
Orozco, O ;
Olson, D ;
De Luca, A ;
Chen, LL ;
Miatkowski, K ;
Benjamin, C ;
Normanno, N ;
Williams, KP ;
Jarpe, M ;
LePage, D ;
Salomon, D ;
Sanicola, M .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (04) :575-587
[3]   SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7 [J].
Byfield, SD ;
Major, C ;
Laping, NJ ;
Roberts, AB .
MOLECULAR PHARMACOLOGY, 2004, 65 (03) :744-752
[4]   Betaglycan localization in the female rat pituitary: Implications for the regulation of follicle-stimulating hormone by inhibin [J].
Chapman, SC ;
Woodruff, TK .
ENDOCRINOLOGY, 2003, 144 (12) :5640-5649
[5]   Regulation of cell proliferation, apoptosis, and carcinogenesis by activin [J].
Chen, YG ;
Lui, HM ;
Lin, SL ;
Lee, JM ;
Ying, SY .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2002, 227 (02) :75-87
[6]   EGF-CFC proteins are essential coreceptors for the TGF-β signals Vg1 and GDF1 [J].
Cheng, SK ;
Olale, F ;
Bennett, JT ;
Brivanlou, AH ;
Schier, AF .
GENES & DEVELOPMENT, 2003, 17 (01) :31-36
[7]   Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice [J].
Cipriano, SC ;
Chen, L ;
Kumar, TR ;
Matzuk, MM .
ENDOCRINOLOGY, 2000, 141 (07) :2319-2327
[8]   Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice [J].
Coerver, KA ;
Woodruff, TK ;
Finegold, MJ ;
Mather, J ;
Bradley, A ;
Matzuk, MM .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (05) :534-543
[9]   PASSIVE IMMUNONEUTRALIZATION WITH A MONOCLONAL-ANTIBODY REVEALS A ROLE FOR ENDOGENOUS ACTIVIN-B IN MEDIATING FSH HYPERSECRETION DURING ESTRUS AND FOLLOWING OVARIECTOMY OF HYPOPHYSECTOMIZED, PITUITARY-GRAFTED RATS [J].
DEPAOLO, LV ;
BALD, LN ;
FENDLY, BM .
ENDOCRINOLOGY, 1992, 130 (03) :1741-1743
[10]   Smads:: Transcriptional activators of TGF-β responses [J].
Derynck, R ;
Zhang, Y ;
Feng, XH .
CELL, 1998, 95 (06) :737-740
1234567